CAP TODAY Webinars

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center, reviews the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis. They also discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Gain practical insights into the HER2 IHC scoring criteria. We will examine stained slides to refine the participant’s ability to apply guidelines with confidence and consistency and learn how to standardize these findings in pathology reports to facilitate high-level multidisciplinary discussions and guide precision treatment decisions.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center, leads a presentation exploring the value of in-house CGP, offers insights into the benefits and drawbacks of incorporation, and provides information about important practical factors when considering in-house implementation of CGP.

Comprehensive genomic profiling (CGP) is a valuable tool for analyzing clinical tumor specimens. Whereas it is most often considered important for the identification of targetable alterations in advanced cancers, it is also proving useful in planning therapeutic regimens in early cancer settings, offering clinical trial enrollment and in the identification of alterations that could change a diagnosis. Integration of CGP into in-house pathology workflows requires thoughtful deliberation, but its implementation can prove very useful to the clinicians, pathologists and patients that it supports. This presentation will discuss the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenters Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian, and David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, explore the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center Department of Pathology, and Molly Epler, MHI, LSSYB, Clinical Laboratory Manager, Wexner Medical Center discuss digital pathology technology that is future-ready, yet practical for today’s laboratory needs, how Ocus M scanner is making DP more accessible, and provide perspective on where DP is headed, including how market developments (e.g. Grundium’s recent acquisition of VisioPharm) may signal broader trends.

Webinar presenter Josef Rüschoff, MD, PhD, Former Chief Medical Officer and Co-Founder of Targos,
Senior Consultant of Discovery Life Sciences, Kassel, Germany. Hear from Dr. Rüschoff, an expert in HER2 IHC, whose work has contributed to current scoring guidelines.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine, Department of Pathology, SOM at Johns Hopkins University, discusses how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center, discusses the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC, discusses how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.